Solid growth company. Well along in clinical trials. Well run and the upside is pretty good. Some good partnerships. Good product. If you want a Cdn biotech, this is a good one.
Has a better product than cyclosporine. This should create a great marketplace for them. With more results coming out in 2004, you should see the stock move-up quite nicely.
Their particular area of expertise is getting involved with drugs that are involved with transplants that reduce rejection. Outlook for the company is quite interesting. In phase 2 and 3 trials so they still have a ways to go. Speculative.
Drug development. Burning up cash hand over fist. In sloppy markets you have to watch out. There's no earnings or fundamental support. Very early stages in drug development and will have to raise money, so will dilute shareholders.
Nothing fundamentally horrible about this company but it does have a small market cap, which is an out-of-favour sector. Small cap biotech sector is not a place to be.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.